{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"12.8","value":"0.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"9.7","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"description":"The percentage of participants who developed collagen as evidenced by trichrome staining, defined as a Grade 4 on the modified Bauermeister grading scale:\n\nGrade 0: No reticulin fibers demonstrable\n\nGrade 1: Occasional fine individual fibers and foci of a fine fiber network\n\nGrade 2: Fine fiber network throughout most of the section; no coarse fibers\n\nGrade 3: Diffuse fiber network with scattered thick coarse fibers but no mature collagen (negative to trichrome staining)\n\nGrade 4: Diffuse, often course fiber network with areas of collagenization (positive trichrome staining)","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants enrolled under the protocol supplement in the EU, Switzerland, or Turkey received weekly romiplostim for 3 years and had a bone marrow biopsy at baseline and year 1.","id":"OG000","title":"Cohort 1"},{"description":"Participants enrolled under the protocol supplement in the EU, Switzerland, or Turkey received weekly romiplostim for 3 years and had a bone marrow biopsy at baseline and year 2.","id":"OG001","title":"Cohort 2"}],"paramType":"NUMBER","populationDescription":"The bone marrow analysis set includes participants who received at least 1 dose of romiplostim, who were recruited within the protocol supplement for the EU, Switzerland and Turkey and who had at least 1 bone marrow biopsy during the study after initiation of study treatment. Participants with available core biopsy results are included.","reportingStatus":"POSTED","timeFrame":"Year 1 (Cohort 1) and year 2 (Cohort 2)","title":"Percentage of Participants Who Developed Collagen After Exposure to Romiplostim","type":"PRIMARY","unitOfMeasure":"percentage of participants"}